CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the āCompanyā), a biotechnology and precision fermentation company focused on using cellular agriculture to produce environmentally-friendly products for human health, has been granted a new patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in āmagicā mushrooms. The patent marks yet another milestone for the Company in its journey to create safe, sustainable, and scalable compounds for various industries, researchers and clinicians.
